Michael H. Kroll MDProfessor of Medicine and Chief, Section of Benign Hematology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Dr. Michael Kroll is a hematologist and oncologist practicing in Houston, Texas. He is Professor of Medicine and Chief of the Section of Benign Hematology at the University of Texas MD Anderson Cancer Center (UTMDACC). His basic research background is in mechanisms of platelet-dependent thrombosis, and his academic clinical niche is benign hematology, hemostasis and thrombosis. His group’s research activities focus on mechanisms of cancer- and stem cell transplant–associated thrombotic microangiopathy, the prevention and treatment of venous thromboembolism in cancer patients, and mechanisms of cancer-induced venous thrombosis.
Dr. Kroll is intimately involved in fellowship training, co-directs UTMDACC’s Anticoagulant Stewardship Program, has published over 100 manuscripts in peer-reviewed journals, lectures world-wide over a dozen times per year, serves on 2 federal grant review committees, has received several awards for education and leadership, and continues to serve The American Society of Hematology in various capacities.
Dr. Kroll received his medical degree from Cornell. He underwent residency training in internal medicine at Brown University and completed his fellowship in hematology/oncology at Harvard Medical School–Brigham & Women's Hospital.
Recent Contributions to PracticeUpdate:
- ASH 2019 Guidelines for Management of VTE: Prevention of VTE in Surgical Hospitalized Patients
- 2019 Top Stories in Benign Hematology: Chemotherapy-Induced Thrombocytopenia
- Costs Associated With Bleeding in Patients on Long-Term Antiplatelets Without Routine Co-Prescription of PPIs
- FDA Approves First Treatment to Increase Pain-Free Light Exposure in Patients With a Rare Disorder
- Treatment Implications of Novel Clinical Phenotypes for Sepsis
- Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated Coagulopathy
- MY APPROACH: Dual Antiplatelet or Antithrombotic Therapy After MI: A Hematologist’s Perspective
- Dual Antiplatelet or Dual Antithrombotic Therapy for Secondary Prevention in High-Risk Patients With Stable CAD
- Caplacizumab Treatment for Acquired TTP
- Anticoagulants for Portal Vein Thrombosis in Cirrhosis